Mitochondrial disease and epilepsy

Developmental Medicine and Child Neurology

Volumn 54, Issue 5, 2012, Pages 397-406

  Rahman, Shamima ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARNITINE; CYTOCHROME C OXIDASE; ETIRACETAM; INSULIN; LAMOTRIGINE; MEMBRANE LIPID; MITOCHONDRIAL ATP SYNTHASE; MITOCHONDRIAL DNA; MITOCHONDRIAL ENZYME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); THYROXINE; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; VALPROIC ACID; VITAMIN;

ALPERS DISEASE; ANTICONVULSANT THERAPY; ATAXIA; BIOSYNTHESIS; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM; CHILD; CHILD NUTRITION; CLINICAL FEATURE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME DEFICIENCY; EPILEPSY; GENE; GENE MUTATION; HEARING AID; HORMONAL THERAPY; HUMAN; KEARNS SAYRE SYNDROME; KETOGENIC DIET; LEIGH DISEASE; LIVER FAILURE; MELAS SYNDROME; MEMSA SYNDROME; MERRF SYNDROME; MITOCHONDRION DNA DEPLETION SYNDROME; MYOCLONUS; MYOPATHY; NARP SYNDROME; NEUROPROTECTION; OXIDATIVE PHOSPHORYLATION; PATIENT MONITORING; PERCEPTION DEAFNESS; POLG1 GENE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY CHAIN; REVIEW; SEIZURE; SPINOCEREBELLAR TRACT; STROKE; SYNDROME; SYNDROME DELINEATION;

ANIMALS; BRAIN DISEASES, METABOLIC, INBORN; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; DNA, MITOCHONDRIAL; EPILEPSY; GENETIC TESTING; GENOTYPE; HUMANS; INFANT; KETOGENIC DIET; MELAS SYNDROME; MICE; MICE, TRANSGENIC; MITOCHONDRIAL DISEASES; MITOCHONDRIAL ENCEPHALOMYOPATHIES; PHENOTYPE; SYNDROME;

EID: 84859511813     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2011.04214.x     Document Type: Review

References (94)

1. Rahman S, Hanna MG. Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial diseases. J Neurol Neurosurg Psychiatry 2009; 80: 943-53.
2. Thorburn DR. Mitochondrial disorders: prevalence, myths and advances. J Inherit Metab Dis 2004; 27: 349-62.
3. Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A->G mutation in European children. N Engl J Med 2009; 360: 640-2.
4. Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008; 134: 112-23.
5. Debray FG, Lambert M, Chevalier I, et al. Long-term outcome and clinical spectrum of 73 paediatric individuals with mitochondrial diseases. Pediatrics 2007; 119: 722-33.
6. Khurana DS, Salganicoff L, Melvin JJ, et al. Epilepsy and respiratory chain defects in children with mitochondrial encephalopathies. Neuropediatrics 2008; 39: 8-13.
7. Parikh S, Cohen BH, Gupta A, Lachhwani DK, Wyllie E, Kotagal P. Metabolic testing in the pediatric epilepsy unit. Pediatr Neurol 2008; 38: 191-5.
8. El Sabbagh S, Lebre AS, Bahi-Buisson N, et al. Epileptic phenotypes in children with respiratory chain disorders. Epilepsia 2010; 51: 1225-35.
9. Lee YM, Kang HC, Lee JS, et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008; 49: 685-90.
10. Canafoglia L, Franceschetti S, Antozzi C, et al. Epileptic phenotypes associated with mitochondrial disorders. Neurology 2001; 56: 1340-6.
11. Wolf NI, Rahman S, Schmitt B, et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009; 50: 1596-607.
12. Calvo SE, Tucker EJ, Compton AG, et al. High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat Genet 2010; 42: 851-8.
13. Liolitsa D, Rahman S, Benton S, Carr LJ, Hanna MG. Is the mitochondrial complex I ND5 gene a hot-spot for MELAS causing mutations? Ann Neurol 2003; 53: 128-32.
14. Naini AB, Lu J, Kaufmann P, et al. Novel mitochondrial DNA ND5 mutation in a patient with clinical features of MELAS and MERRF. Arch Neurol 2005; 62: 473-6.
15. Schuelke M, Smeitink J, Mariman E, et al. Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. Nat Genet 1999; 21: 260-1.
16. van den Heuvel L, Ruitenbeek W, Smeets R, et al. Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. Am J Hum Genet 1998; 62: 262-8.
17. Loeffen J, Smeitink J, Triepels R, et al. The first nuclear-encoded complex I mutation in a individual with Leigh syndrome. Am J Hum Genet 1998; 63: 1598-608.
18. Fernandez-Moreira D, Ugalde C, Smeets R, et al. X-linked NDUFA1 gene mutations associated with mitochondrial encephalomyopathy. Ann Neurol 2007; 61: 73-83.
19. Fassone E, Duncan AJ, Taanman JW, et al. FOXRED1, encoding an FAD-dependent oxidoreductase complex-I-specific molecular chaperone, is mutated in infantile-onset mitochondrial encephalopathy. Hum Mol Genet 2010; 19: 4837-47.
20. Nouws J, Nijtmans L, Houten SM, et al. Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. Cell Metab 2010; 12: 283-94.
21. Barghuti F, Elian K, Gomori JM, et al. The unique neuroradiology of complex I deficiency due to NDUFA12L defect. Mol Genet Metab 2008; 94: 78-82.
22. Saada A, Vogel RO, Hoefs SJ, et al. Mutations in NDUFAF3 (C3ORF60), encoding an NDUFAF4 (C6ORF66)-interacting complex I assembly protein, cause fatal neonatal mitochondrial disease. Am J Hum Genet 2009; 84: 718-27.
23. Saada A, Edvardson S, Rapoport M, et al. C6ORF66 is an assembly factor of mitochondrial complex I. Am J Hum Genet 2008; 82: 32-8.
24. Horvath R, Abicht A, Holinski-Feder E, et al. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). J Neurol Neurosurg Psychiatry 2006; 77: 74-6.
25. Fernandez-Vizarra E, Bugiani M, Goffrini P, et al. Impaired complex III assembly associated with BCS1L gene mutations in isolated mitochondrial encephalopathy. Hum Mol Genet 2007; 16: 1241-52.
26. Tam EW, Feigenbaum A, Addis JB, et al. A novel mitochondrial DNA mutation in COX1 leads to strokes, seizures, and lactic acidosis. Neuropediatrics 2008; 39: 328-34.
27. Tiranti V, Jaksch M, Hofmann S, et al. Loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome c oxidase deficiency. Ann Neurol 1999; 46: 161-6.
28. Sue CM, Karadimas C, Checcarelli N, et al. Differential features of patients with mutations in two COX assembly genes, SURF-1 and SCO2. Ann Neurol 2000; 47: 589-95.
29. Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 1996; 39: 343-51.
30. Zhang Y, Yang YL, Sun F, et al. Clinical and molecular survey in 124 Chinese patients with Leigh or Leigh-like syndrome. J Inherit Metab Dis 2007; 30: 265.
31. Huigsloot M, Nijtmans LG, Szklarczyk R, et al. A mutation in c2orf64 causes impaired cytochrome C oxidase assembly and mitochondrial cardiomyopathy. Am J Hum Genet 2011; 88: 488-93.
32. Ghezzi D, Saada A, D'Adamo P, et al. FASTKD2 nonsense mutation in an infantile mitochondrial encephalomyopathy associated with cytochrome c oxidase deficiency. Am J Hum Genet 2008; 83: 415-23.
33. Jaksch M, Ogilvie I, Yao J, et al. Mutations in SCO2 are associated with a distinct form of hypertrophic cardiomyopathy and cytochrome c oxidase deficiency. Hum Mol Genet 2000; 9: 795-801.
34. Valnot I, Von Kleist-Retzow JC, Barrientos A, et al. A mutation in the human heme A:farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency. Hum Mol Genet 2000; 9: 1245-9.
35. Antonicka H, Mattman A, Carlson CG, et al. Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. Am J Hum Genet 2003; 72: 101-14.
36. Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428-33.
37. Thorburn DR, Rahman S. Mitochondrial DNA-associated Leigh Syndrome and NARP. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle, WA: University of Washington, 1993. (accessed 24 August 2011).
38. De Meirleir L, Seneca S, Lissens W, et al. Respiratory chain complex V deficiency due to a mutation in the assembly gene ATP12. J Med Genet 2004; 41: 120-4.
39. Spiegel R, Khayat M, Shalev SA, et al. TMEM70 mutations are a common cause of nuclear encoded ATP synthase assembly defect: further delineation of a new syndrome. J Med Genet 2011; 48: 177-82.
40. Rahman S, Poulton J. Diagnosis of mitochondrial DNA depletion syndromes. Arch Dis Child 2009; 94: 3-5.
41. Taanman JW, Rahman S, Pagnamenta AT, et al. Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion. Hum Mutat 2009; 30: 248-54.
42. Harding BN. Progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher syndrome): a personal review. J Child Neurol 1990; 5: 273-87.
43. Cohen BH, Chinnery PF, Copeland WC. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle, WA: University of Washington, 1993. (accessed 24 August 2011).
44. Saneto RP, Naviaux RK. Polymerase gamma disease through the ages. Dev Disabil Res Rev 2010; 16: 163-74.
45. Hakonen AH, Isohanni P, Paetau A, Herva R, Suomalainen A, Lonnqvist T. Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion. Brain 2007; 130: 3032-40.
46. Nikali K, Suomalainen A, Saharinen J, et al. Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins Twinkle and Twinky. Hum Mol Genet 2005; 14: 2981-90.
47. Sarzi E, Goffart S, Serre V, et al. Twinkle helicase (PEO1) gene mutation causes mitochondrial DNA depletion. Ann Neurol 2007; 62: 579-87.
48. Bourdon A, Minai L, Serre V, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 2007; 39: 776-80.
49. Elpeleg O, Miller C, Hershkovitz E, et al. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet 2005; 76: 1081-6.
50. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990; 348: 651-3.
51. Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990; 61: 931-7.
52. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005; 4: 239-48.
53. Jaksch M, Klopstock T, Kurlemann G, et al. Progressive myoclonus epilepsy and mitochondrial myopathy associated with mutations in the tRNA(Ser(UCN)) gene. Ann Neurol 1998; 44: 635-40.
54. Chrzanowska-Lightowlers ZM, Horvath R, Lightowlers RN. 175th ENMC International Workshop: mitochondrial protein synthesis in health and disease, 25-27th June 2010, Naarden, The Netherlands. Neuromuscul Disord 2011; 21: 142-7.
55. Edvardson S, Shaag A, Kolesnikova O, et al. Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am J Hum Genet 2007; 81: 857-62.
56. Rankin J, Brown R, Dobyns WB, et al. Pontocerebellar hypoplasia type 6: a British case with PEHO-like features. Am J Med Genet A 2010; 152A: 2079-84.
57. Glamuzina E, Brown RM, Pitt M, et al. Expanding the phenotype of Pontocerebellar Hypoplasia type 6 secondary to mutations in the mitochondrial arginyl-tRNA synthetase gene RARS2. J Inherit Metab Dis 2011 Nov 16 (Epub ahead of print).
58. Smeitink JA, Elpeleg O, Antonicka H, et al. Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am J Hum Genet 2006; 79: 869-77.
59. 10 deficiency. Neuromuscul Disord 2011 Jun 30 (Epub ahead of print).
60. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA 1989; 86: 2379-82.
61. Lopez LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006; 79: 1125-9.
62. Quinzii C, Naini A, Salviati L, et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006; 78: 345-9.
63. Mollet J, Giurgea I, Schlemmer D, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest 2007; 117: 765-72.
64. Duncan AJ, Bitner-Glindzicz M, Meunier B, et al. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet 2009; 84: 558-66.
65. Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 2011; 121: 2013-24.
66. Mollet J, Delahodde A, Serre V, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet 2008; 82: 623-30.
67. Lagier-Tourenne C, Tazir M, Lopez LC, et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet 2008; 82: 661-72.
68. Molinari F, Raas-Rothschild A, Rio M, et al. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet 2005; 76: 334-9.
69. Molinari F, Kaminska A, Fiermonte G, et al. Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts. Clin Genet 2009; 76: 188-94.
70. Yamamoto H, Tang HW. Preventive effect of melatonin against cyanide-induced seizures and lipid peroxidation in mice. Neurosci Lett 1996; 207: 89-92.
71. Urbanska EM, Blaszczak P, Saran T, Kleinrok Z, Turski WA. Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice. Eur J Pharmacol 1998; 359: 55-8.
72. Kunz WS. The role of mitochondria in epileptogenesis. Curr Opin Neurol 2002; 15: 179-84.
73. Harris MO, Walsh LE, Hattab EM, Golomb MR. Is it ADEM, POLG, or both? Arch Neurol 2010; 67: 493-6.
74. Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007; 22: 105-9.
75. Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997; 156: 562-4.
76. Galimberti CA, Diegoli M, Sartori I, et al. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation. Neurology 2006; 67: 1715-7.
77. Chabrol B, Mancini J, Chretien D, Rustin P, Munnich A, Pinsard N. Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 1994; 153: 133-5.
78. Isohanni P, Hakonen AH, Euro L, et al. POLG1 manifestations in childhood. Neurology 2011; 76: 811-5.
79. Uusimaa J, Hinttala R, Rantala H, et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia 2008; 49: 1038-45.
80. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009; 47: 101-11.
81. Mancuso M, Galli R, Pizzanelli C, Filosto M, Siciliano G, Murri L. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006; 243: 97-9.
82. Arpin S, Lagrue E, Bodard S, Chalon S, Castelnau P. Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study. Metab Brain Dis 2009; 24: 453-61.
83. Koga Y, Akita Y, Nishioka J, et al. MELAS and l-arginine therapy. Mitochondrion 2007; 7: 133-9.
84. Pineda M, Ormazabal A, Lopez-Gallardo E, et al. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann Neurol 2006; 59: 394-8.
85. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006; 1: CD004426.
86. Santra S, Gilkerson RW, Davidson M, Schon EA. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 2004; 5: 662-9.
87. Ahola-Erkkila S, Carroll CJ, Peltola-Mjosund K, et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 2010; 19: 1974-84.
88. Tyynismaa H, Mjosund KP, Wanrooij S, et al. Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc Natl Acad Sci USA 2005; 102: 17687-92.
89. Joshi CN, Greenberg CR, Mhanni AA, Salman MS. Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol 2009; 40: 314-6.
90. Kang HC, Lee YM, Kim HD, Lee JS, Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007; 48: 82-8.
91. Kollberg G, Darin N, Benan K, et al. A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. Neuromuscul Disord 2009; 19: 147-50.
92. Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005; 65: 606-8.
93. Rahman S, Hargreaves I, Clayton P, Heales S. Neonatal presentation of coenzyme Q10 deficiency. J Pediatr 2001; 139: 456-8.
94. Ghezzi D, Sevrioukova I, Invernizzi F, et al. Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. Am J Hum Genet 2010; 86: 639-49.